Lorenza Rimassa at Humanitas University - Research Interests, Publications & Academic Profile

Lorenza Rimassa

Humanitas University

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Continue in dashboard

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

90%

Immunology

50%

Hepatology

100%

Oncology

90%

Cancer Therapy

70%

Cancer Biology

70%

Pancreatic Cancer

50%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles21

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma

Article Link

Year:

2024

Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices

Article Link

Year:

2024

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Article Link

Year:

2024

New systemic treatment options for advanced cholangiocarcinoma

Article Link

Year:

2024

Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer

Article Link

Year:

2024

Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Article Link

Year:

2024

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

Article Link

Year:

2024

CT-based radiogenomics of intrahepatic cholangiocarcinoma

Article Link

Year:

2024

The tumor microenvironment of VETC+ hepatocellular carcinoma is enriched of immunosuppressive TAMs spatially close to endothelial cells

Article Link

Year:

2024

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Article Link

Year:

2024

Network meta-analysis: A map to navigate the maze of treatment for advanced hepatocellular carcinoma

Article Link

Year:

2023

Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study).

Article Link

Year:

2023

Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?

Article Link

Year:

2023

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.

Article Link

Year:

2023

Identification of Atezolizumab Plus Bevacizumab Prognostic Index <i>via</i> Recursive Partitioning Analysis in HCC: The ABE Index.

Article Link

Year:

2023

Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Article Link

Year:

2023

Combination immunotherapy for hepatocellular carcinoma

Article Link

Year:

2023

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment

Article Link

Year:

2023

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Article Link

Year:

2023

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

Article Link

Year:

2023

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

Article Link

Year:

2023

Collaborators12

Armando Santoro

Professore

Humanitas University

ITALY

View Details

ciro franzese

Assistant Professor

Humanitas University

ITALY

View Details

Ferran Torres

Universitat Autònoma de Barcelona (UAB)

SPAIN

View Details

Najib Ben Khaled

GERMANY

View Details

Bruno Sangro

SPAIN

View Details

Maria Reig

Head of the Liver Oncology group-CIBER

SPAIN

View Details

Alessio Cortellini

Imperial College London

UNITED KINGDOM

View Details

Margherita Rimini

ITALY

View Details

Enrico N De Toni

University Hospital

GERMANY

View Details

Giuseppe Cabibbo

University of Palermo

ITALY

View Details

Andrea Casadei-Gardini

ITALY

View Details

Antonio D'Alessio

Imperial College London

UNITED KINGDOM

View Details

How do I reach out?

Continue in dashboard